Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: Renovis

No earlier versions found for this Subject.

Return to Renovis

Renovis Inc is scheduled to go public next week.

Offering Date: 2/4/2004
Price Range: $13-15
Shares: 5,500,000
Shares Outstanding after IPO: Approx 23 million

Lead Underwriter: Goldman Sachs
Web Site: www.renovis.com

Renovis is a biopharmaceutical company developing drugs to treat neurological diseases and disorders. We are currently pursuing eight distinct programs, including three product candidates in clinical development. Our most advanced product candidate is Cerovive®, an intravenous drug for acute ischemic stroke, being evaluated in a Phase III clinical trial program by our exclusive licensee, AstraZeneca. We are also independently developing two product candidates for the treatment of pain: REN-1654, an oral drug for neuropathic pain in Phase II clinical trials, and REN-213, an intravenous drug for acute post-operative pain also in Phase II clinical trials.

Any thoughts or comments on this IPO?